Itzchak Angel , Ph.D.

Chief Scientific Advisor

Itzchak Angel is an accomplished executive in the Pharmaceutical Industry, with over 40 years’ experience in guiding medical, pharmaceutical, drug- and business- development in both large and emerging companies. Since 2005, he has been President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.)  where he assists pharmaceutical or biotechnology companies, individuals, medical staff, hospitals, technology transfer companies, investors, university researchers and research teams in variable aspects of drug development. Under this function, he gives consultation to and assist Life Sciences companies in Strategic and Operational issues related to Ethical Drug Development (from Research through Preclinical and Clinical, up to marketing), Regulatory Affaires, Business Development and Planning and Organization, ranging in many diverse therapeutic indication and pharmacological families.

Dr. Angel’s journey in the sciences began with his education at the Tel-Aviv university, where he earned his B. Sc, and M.Sc. degrees in Biology in 1979 and 1980, taking part in a special curriculum for outstanding students. He further studied at the Hamburg University, Germany, obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda, Maryland where he pursued his research on Neurobiology. For numerous years, he was Head of Pharmacology in Synthelabo (Sanofi-Aventis, Paris, France) where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem) and Mizollen (mizolastine). To name some of Dr Angel’s executive functions, he has formerly been President and Chief executive Officer of the stem-cell company Accellta (Haifa, Israel), Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals and at D-Pharm Biopharmaceuticals (Rehovot, Israel) where he has been involved in research and advanced development in several areas such as Stroke, Epilepsy, Alzheimer’s’ Disease, Parkinson’s disease, metabolic disorders, psoriasis and Cancers.

Effectively established Discovery, Research and Development teams and projects and brought several pharmaceutical drugs to market. Excellent communicator and negotiator who led international projects and interfaced with high profile regulatory, government and industry leaders.

Dr. Angel is author of more than 100 book chapters, papers, abstracts and patents. He is also a passionate painter, music lover, avid traveler who speaks many languages.

Ms. Yanez earned her B.A. in Business Management from University South Florida and further distinguished her acumen with an MBA in Strategic Leadership from Rutgers School of Business, Cum Laude.